Vildagliptin
- Generic Name
- Vildagliptin
- Brand Names
- Galvus, Jalra, Xiliarx
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O2
- CAS Number
- 274901-16-5
- Unique Ingredient Identifier
- I6B4B2U96P
- Background
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependen...
- Indication
Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thi...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Glucose Control in Pre-Diabetic Renal Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- Marcus Saemann
- Target Recruit Count
- 51
- Registration Number
- NCT01346254
- Locations
- 🇦🇹
Allgemeines Krankenhaus der Stadt Wien, Universitätskliniken, Wien, Austria
Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT01262586
- Locations
- 🇩🇪
Novartis Investigative Site, Mainz, Germany
Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 431
- Registration Number
- NCT01257451
- Locations
- 🇬🇧
Novartis Investigative Site, Wiltshire, United Kingdom
Phase 4 Study in the Elderly Patients With T2DM
- Conditions
- Interventions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 46
- Registration Number
- NCT01238978
- Locations
- 🇫🇷
Novartis Investigative Site #2, Venissieux, France
🇫🇷Novartis Investigative Site, Versailles, France
Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 317
- Registration Number
- NCT01233622
- Locations
- 🇨🇳
Novartis Investigative Site, Yongkang, Taiwan
🇲🇽Novartis Investigative Site #3, Pachuca, Mexico
🇲🇽Novartis Investigative Site #5, Guadalajara, Mexico
Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 448
- Registration Number
- NCT01224366
- Locations
- 🇬🇧
Novartis Investigative Site, Carmarthen, United Kingdom
🇸🇰Novartis Investigative Site #3, Bratislava, Slovakia
🇬🇧Novartis Investigative Site #2, Glasgow, United Kingdom
Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Lund University
- Target Recruit Count
- 28
- Registration Number
- NCT01219400
- Locations
- 🇸🇪
Lund University, Lund, Sweden
Glycemic Holter Study (Continuous Glucose Monitoring) -
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 36
- Registration Number
- NCT01193296
- Locations
- 🇫🇷
Investigative Site, Venissieux, France
Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 245
- Registration Number
- NCT01159249
- Locations
- 🇯🇵
Novartis Investigative Site, Fukuoka, Japan
Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2012-09-25
- Lead Sponsor
- Lund University
- Target Recruit Count
- 28
- Registration Number
- NCT01147276
- Locations
- 🇸🇪
Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.